Korean J Urol.  2014 Mar;55(3):222-225. 10.4111/kju.2014.55.3.222.

Metastasis of Non-Muscle-Invasive Bladder Cancer Into the Thyroid Gland: A Literature Review Accompanied by a Rare Case

• Tuncer M
• Faydaci G
• Altin G
• Erdogan BA
• Kibar S
• Sanli A
• Bilgici D

• KMID: 1988429
• DOI: http://doi.org/10.4111/kju.2014.55.3.222

Abstract

Bladder cancer is the most prevalent malignancy of the urinary tract. About 90% of bladder cancers are urothelial carcinomas. Seventy percent of cases newly diagnosed are superficial diseases; roughly 30% of newly diagnosed cases are muscle-invasive metastatic diseases. Bladder urothelial carcinoma primarily metastasizes into regional lymph nodes and then into liver, lung, mediastinum, bone, and adrenal gland. In our case, non-muscle-invasive bladder cancer metastasized into the bone, mediastinum, iliac lymph node, and adrenal and thyroid glands. This is the first reported case in the current literature in which urothelial carcinoma metastasized into the thyroid gland.

Keyword

Neoplasm metastasis; Thyroid gland; Urinary bladder neoplasms

MeSH Terms

Adrenal Glands
Liver
Lung
Lymph Nodes
Mediastinum
Neoplasm Metastasis*
Thyroid Gland*
Urinary Bladder Neoplasms*
Urinary Bladder*
Urinary Tract

Figure

• 

  FIG. 1 Bladder transurethral resection biopsy: high-grade urothelial carcinoma with invasion of the lamina propria by malignant epithelial tumor cells with large, pleomorphic nuclei (H&E, ×200).

• 

  FIG. 2 Costal bone biopsy: metastasis of urothelial carcinoma. Malignant epithelial tumor cells show a papillar configuration into the bone trabeculae (H&E, ×100).

• 

  FIG. 3 Thyroid fine needle aspiration biopsy: groups of malignant tumor cells with large pleomorphic nuclei are shown (MGG, ×400).

Reference

1. Ferlay J, Randi G, Bosetti C, Levi F, Negri E, Boyle P, et al. Declining mortality from bladder cancer in Europe. BJU Int. 2008; 101:11–19.

2. Dougherty DW, Gonsorcik VK, Harpster LE, Trussell JC, Drabick JJ. Superficial bladder cancer metastatic to the lungs: two case reports and review of the literature. Urology. 2009; 73:210.e3–210.e5.

3. Alexander PW, Sanders C, Nath H. Cavitary pulmonary metastases in transitional cell carcinoma of urinary bladder. AJR Am J Roentgenol. 1990; 154:493–494.

4. Nishiyama H, Habuchi T, Watanabe J, Teramukai S, Tada H, Ono Y, et al. Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990-2000 in Japan. Eur Urol. 2004; 45:176–181.

5. Gwynn ES, Clark PE. Bladder cancer. Curr Opin Oncol. 2006; 18:277–283.

6. Kardar AH, Lindstedt EM, Tulbah AM, Bazarbashi SN, al Suhaibani HS. Metastatic transitional cell carcinoma of the ovary from superficial bladder tumour. Scand J Urol Nephrol. 1998; 32:73–76.

7. Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001; 166:490–493.

8. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59:997–1008.

9. Puente S, Velasco A, Gallel P, Pallares J, Perez-Ruiz L, Ros S, et al. Metastatic small cell carcinoma to the thyroid gland: a pathologic and molecular study demonstrating the origin in the urinary bladder. Endocr Pathol. 2008; 19:190–196.

10. Schröder S, Wodzynski A, Padberg B. Cytokeratin expression of benign and malignant epithelial thyroid gland tumors: an immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies. Pathologe. 1996; 17:425–432.